<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39354416</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis.</ArticleTitle><Pagination><StartPage>1087</StartPage><MedlinePgn>1087</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1087</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09960-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Drug-resistant tuberculosis (DR-TB) remains a threat to public health. Shorter regimens have been proposed as potentially valuable treatments for multidrug or rifampicin resistant tuberculosis (MDR/RR-TB). We undertook a systematic review and network meta-analysis to evaluate the efficacy and safety of shorter MDR/RR-TB regimens.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched PubMed/MEDLINE, Cochrane Center for Clinical Trials (CENTRAL), Scopus, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, US Food and Drug Administration, and Chinese Clinical Trial Registry for primary articles published from 2013 to July 2023. Favorable (cured and treatment completed) and unfavorable (treatment failure, death, loss to follow-up, and culture conversion) outcomes were assessed as the main efficacy outcomes, while adverse events were assessed as the safety outcomes. The network meta-analysis was performed using R Studio version 4.3.1 and the Netmeta package. The study protocol adhered to the PRISMA-NMA guidelines and was registered in PROSPERO (CRD42023434050).</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">We included 11 eligible studies (4 randomized control trials and 7 cohorts) that enrolled 3,548 patients with MDR/RR-TB. Treatment with a 6-month combination of BdqLzdLfxZTrd/Eto/H had two times more favorable outcomes [RR 2.2 (95% CI 1.22, 4.13), P = 0.0094], followed by a 9-11 month combination of km/CmMfx/LfxPtoCfzZEHh [RR1.67 (95% CI 1.45, 1.92), P &lt; 0.001] and a 6-month BdqPaLzdMfx [RR 1.64 (95% CI 1.24, 2.16), P &lt; 0.0005] compared to the standard longer regimens. Treatment with 6 months of BdqPaLzdMfx [RR 0.33 (95% CI 0.2, 0.55), P &lt; 0.0001] had a low risk of severe adverse events, followed by 6 months of BdqPaLzd [RR 0.36 (95% CI 0.22, 0.59), P ≤ 0.001] and BdqPaLzdCfz [RR 0.54 (95% CI 0.37, 0.80), P &lt; 0.0001] than standard of care.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment of patients with RR/MDR-TB using shorter regimens of 6 months BdqLzdLfxZTrd/Eto/H, 9-11 months km/CmMfx/LfxPtoCfzZEHh, and 6 months BdqPaLzdMfx provides significantly higher cure and treatment completion rates compared to the standard longer MDR/RR-TB. However, 6BdqPaLzdMfx, 6BdqPaLzd, and 6BdqPaLzdCfz short regimens are significantly associated with decreased severity of adverse events. The findings are in support of the current WHO-recommended 6-month shorter regimens.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Yishak</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, P.O. Box 9086, Addis Ababa, Ethiopia. yismay7@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assefa</LastName><ForeName>Dawit Getachew</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Nursing, College of Medicine and Health Science, Dilla University, Dilla, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hailemariam</LastName><ForeName>Tesfahunegn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, P.O. Box 9086, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebrie</LastName><ForeName>Desye</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>College of Health Science and Medicine, Department of Pharmacy, Woldia University, Woldia, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debela</LastName><ForeName>Dejene Tolossa</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Quality Improvement Unit, Shenen Gibe General Hospital, Jimma, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geleta</LastName><ForeName>Simon Tsegaye</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Redat Health Care, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tesfaye</LastName><ForeName>Dagmawit</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, P.O. Box 9086, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, P.O. Box 9086, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manyazewal</LastName><ForeName>Tsegahun</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, P.O. Box 9086, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>VJT6J7R4TR</RegistryNumber><NameOfSubstance UI="D012293">Rifampin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018088" MajorTopicYN="Y">Tuberculosis, Multidrug-Resistant</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012293" MajorTopicYN="Y">Rifampin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="Y">Antitubercular Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071076" MajorTopicYN="Y">Network Meta-Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009169" MajorTopicYN="N">Mycobacterium tuberculosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Multidrug-resistant tuberculosis (MDR-TB)</Keyword><Keyword MajorTopicYN="N">Network meta-analysis</Keyword><Keyword MajorTopicYN="N">Rifampicin-resistant tuberculosis (RR-TB)</Keyword><Keyword MajorTopicYN="N">Short- term regimens</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39354416</ArticleId><ArticleId IdType="pmc">PMC11443784</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09960-3</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09960-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global tuberculosis report 2023.World Health Organization. 2023.https://www.who.int/publications-detail-redirect/9789240083851. Cited 2023 Nov 13.</Citation></Reference><Reference><Citation>Migliori GB, Tiberi S. WHO drug-resistant TB guidelines 2022: what is new? Int J Tuberc Lung Dis. 2022;26(7):590–1.</Citation><ArticleIdList><ArticleId IdType="pubmed">35768917</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization WH. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. In: WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35727905</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization. 2019. In. https://www.ncbi.nlm.nih.gov/books/NBK539518/table/ch1.tab2/.</Citation><ArticleIdList><ArticleId IdType="pubmed">30946559</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. Evans C, editor. PLoS Med. 2012;9(8):e1001300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3429397</ArticleId><ArticleId IdType="pubmed">22952439</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis − 2011 update. 2011;(WHO/HTM/TB/2011.6). Available from: https://apps.who.int/iris/handle/10665/44597. Cited 2023 Jul 16.</Citation><ArticleIdList><ArticleId IdType="pubmed">23844450</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Global Tuberculosis Report 2016. Geneva: World Health, Organization. 2016. - Google Search. https://www.google.com/search?client=firefox-b-d&amp;q=World+Health+Organization.+Global+Tuberculosis+Report+2016.+Geneva%3A+World+Health+Organization%2C+2016. Cited 2023 Jul 16.</Citation></Reference><Reference><Citation>Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis. 2010;14(3):275–81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20132617</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis. 2004;8(11):1382–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15581210</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahardani PN, Wati DK, Siloam A, Savitri NPA, Manggala AK. Effectiveness and safety of short-term regimen for Multidrug-resistant tuberculosis treatment: a systematic review of ohort studies. Oman Med J. 2022;37(1):e337–337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8842242</ArticleId><ArticleId IdType="pubmed">35211341</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249–59.</Citation><ArticleIdList><ArticleId IdType="pubmed">30630778</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT03086486. Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix). 2017. https://clinicaltrials.gov/show/NCT03086486. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01562771/full.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/central/CN-01562771/full</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, et al. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (treatment shortening of MDR-TB using existing and New drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials. 2019;20(1):57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6335682</ArticleId><ArticleId IdType="pubmed">30651149</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, et al. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021;22(1). Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02321533/full.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/central/CN-02321533/full</ArticleId><ArticleId IdType="pmc">PMC8465691</ArticleId><ArticleId IdType="pubmed">34563240</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, et al. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials. 2017;18(1):563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5702225</ArticleId><ArticleId IdType="pubmed">29178937</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng T, Sun F, Li Y, Chen J, Chen X, Li R, et al. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial. BMC Infect Dis. 2021;21(1):183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7888137</ArticleId><ArticleId IdType="pubmed">33596848</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossato Silva D, Carvalho De Queiroz Mello F, Battista Migliori G. Shortened tuberculosis treatment regimens: what is new? J Bras Pneumol. 2020;46(2):e20200009–20200009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462706</ArticleId><ArticleId IdType="pubmed">32215450</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh T, et al. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials. 2022;23(1):484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9190445</ArticleId><ArticleId IdType="pubmed">35698158</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyang’wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, all-oral regimen for Rifampin-resistant tuberculosis. N Engl J Med. 2022;387(25):2331–43.</Citation><ArticleIdList><ArticleId IdType="pubmed">36546625</ArticleId></ArticleIdList></Reference><Reference><Citation>Conradie F, Everitt D, Olugbosi M, Wills G, Fabiane S, Timm J et al. High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid. J Int AIDS Soc. 2021;24(SUPPL 4). https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02348434/full.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/central/CN-02348434/full</ArticleId></ArticleIdList></Reference><Reference><Citation>Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline–Pretomanid–Linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9490302</ArticleId><ArticleId IdType="pubmed">36053506</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmail A, Oelofse S, Lombard C, Perumal R, Mbuthini L, Goolam Mahomed A, et al. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study). Am J Respir Crit Care Med. 2022;205(10):1214–27.</Citation><ArticleIdList><ArticleId IdType="pubmed">35175905</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A trial of a shorter regimen for Rifampin-resistant tuberculosis. N Engl J Med. 2019;380(13):1201–13.</Citation><ArticleIdList><ArticleId IdType="pubmed">30865791</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet. 2022;400(10362):1522–30.</Citation><ArticleIdList><ArticleId IdType="pubmed">36522208</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Qiu C, Chen X, Wang J, Jing W, Pan H, et al. Treatment outcome of a shorter regimen containing clofazimine for multidrug-resistant tuberculosis: a randomized control trial in China. Clin Infect Dis. 2020;71(4):1047–54.</Citation><ArticleIdList><ArticleId IdType="pubmed">31549147</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassane-Harouna S, Cherif GF, Ortuno-Gutierrez N, Cisse D, Camara LM, Diallo BD, et al. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: a retrospective cohort study. Ehtesham HS, editor. PLOS ONE. 2020;15(8):e0237355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7416929</ArticleId><ArticleId IdType="pubmed">32776969</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Cros P, Khamraev A, Lister D, Ronnachit A, Berry C, Greig J, Parpieva N, Tillyashaykhov M, Cooke G, Dietrich S, Pylypenko T, Tigay Z, Achar J. (n.d.). Comparing shorter with conventional MDR-TB treatment in Uzbekistan: 2-month culture-conversion rates and treatment outcomes. https://d1hiluowqo0t4b.cloudfront.net/posters/docs/f1000research-164246.pdf [Accessed 7 Oct 2023].</Citation></Reference><Reference><Citation>Mleoh L, Mziray SR, Tsere D, Koppelaar I, Mulder C, Lyakurwa D. Shorter regimens improved treatment outcomes of multidrug-resistant tuberculosis patients in Tanzania in 2018 cohort. Trop Med Int Health. 2023;28(5):357–66.</Citation><ArticleIdList><ArticleId IdType="pubmed">36864011</ArticleId></ArticleIdList></Reference><Reference><Citation>Myemba DT, Bwire GM, Sambayi G, Maganda BA, Njiro BJ, Ndumwa HP, et al. Clinical characteristics and treatment outcomes of patients with MDR Tuberculosis in Dar Es Salaam region, Tanzania. JAC-Antimicrob Resist. 2020;2(4):dlaa108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8210025</ArticleId><ArticleId IdType="pubmed">34223058</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid A, Ghafoor A, Khan AW, Al-Worafi YM, Latif A, Shahwani NA, et al. Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country. Front Pharmacol. 2022;13:973713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9503836</ArticleId><ArticleId IdType="pubmed">36160454</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhdanova E, Goncharova O, Davtyan H, Alaverdyan S, Sargsyan A, Harries AD, et al. 9–12 months short treatment for patients with MDR-TB increases treatment success in Kyrgyzstan. J Infect Dev Ctries. 2021;15(091):S66–74.</Citation><ArticleIdList><ArticleId IdType="pubmed">34609962</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.</Citation><ArticleIdList><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Division of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases National Institutes of Health, US Department of Health and Human Services. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Vol. corrected version 2.1. 2017. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf.</Citation></Reference><Reference><Citation>World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision: updated December 2014 and January 2020. Définitions et cadre de notification pour la tuberculose – révision 2013. Geneva: World Health Organization; 2013. Available from: https://iris.who.int/handle/10665/79199. Cited 5 Jul 2024.</Citation></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane Handbook for Systematic Reviews of Interventions. 1st ed. Wiley; 2019. https://onlinelibrary.wiley.com/doi/book/10.1002/9781119536604. Cited 2023 Jul 27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9781119536604</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Hernán MA, McAleenan A, Reeves BC, Higgins JPT. Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. www.training.cochrane.org/handbook</Citation></Reference><Reference><Citation>Efthimiou O, Mavridis D, Debray TPA, Samara M, Belger M, Siontis GCM, et al. Combining randomized and non-randomized evidence in network meta‐analysis. Stat Med. 2017;36(8):1210–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">28083901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatami H, Sotgiu G, Bostanghadiri N, Abadi SS, Mesgarpour B, Goudarzi H, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48:e20210384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8836629</ArticleId><ArticleId IdType="pubmed">35649043</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv L, Li T, Xu K, Shi P, He B, Kong W, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist. 2018;11:147–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790105</ArticleId><ArticleId IdType="pubmed">29416359</ArticleId></ArticleIdList></Reference><Reference><Citation>Basit A, Ahmad N, Khan AH, Javaid A, Syed Sulaiman SA, Afridi AK, et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PLoS ONE. 2014;9(4):e93206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976287</ArticleId><ArticleId IdType="pubmed">24705411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad Khan F, Salim MAH, Du Cros P, Casas EC, Khamraev A, Sikhondze W, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J. 2017;50(1):1700061.</Citation><ArticleIdList><ArticleId IdType="pubmed">28751411</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong E, Wu Q, Chen Y, Liu Z, Zhang M, Zhu Y, et al. The efficacy and safety of Bedaquiline in the treatment of pulmonary tuberculosis patients: a systematic review and Meta-analysis. Antibiotics. 2023;12(9):1389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10525131</ArticleId><ArticleId IdType="pubmed">37760686</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Falagas ME, Vardakas KZ, Wang R, Qin R, Wang J, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015;7(4):603–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419320</ArticleId><ArticleId IdType="pubmed">25973226</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasiri MJ, Zangiabadian M, Arabpour E, Amini S, Khalili F, Centis R, et al. Delamanid-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2022;124:S90–103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9731904</ArticleId><ArticleId IdType="pubmed">35245659</ArticleId></ArticleIdList></Reference><Reference><Citation>Labuda SM, Seaworth B, Dasgupta S, Goswami ND. Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis. Lancet Respir Med. 2024;12(2):e5–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">38043563</ArticleId></ArticleIdList></Reference><Reference><Citation>Van De Berg SEJ, Pelzer PT, Van Der Land AJ, Abdrakhmanova E, Ozi AM, Arias M, et al. Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients. BMC Public Health. 2021;21(1):1404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8284025</ArticleId><ArticleId IdType="pubmed">34271884</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, Dodd M, et al. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis. Muniyandi M, editor. PLOS Glob Public Health. 2022;2(12):e0001337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10022130</ArticleId><ArticleId IdType="pubmed">36962909</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>